Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in Virus-Associated Lymphomas
share announcement

Advances in Virus-Associated Lymphomas

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Infectious Agents and Cancer".

Deadline for manuscript submissions: closed (1 March 2023) | Viewed by 2073

Special Issue Editor

Dr. José-Tomás Navarro

E-Mail Website
Guest Editor
1. Lymphoid Neoplasms Group, Josep Carreras Leukaemia Research Institute, Can Ruti Campus, 08916 Badalona, Spain
2. Department of Hematology, Institut Català d’Oncologia-Germans Trias i Pujol Hospital, 08916 Badalona, Spain
3. Department of Medicine, Universitat Autònoma de Barcelona, 08916 Badalona, Spain
Interests: lymphoma; virus; etiopathogenesis; treatment; prognosis; Epstein–Barr virus; HIV; HHV-8; HTLV-I; HCV
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Some viruses have been classically associated with lymphoma. Some of them have already been demonstrated to have an etiopathogenic role in the development of some lymphoma types, such as Epstein–Barr virus through its latent proteins. However, the specific contribution of some viruses to the development of some lymphomas is not well established. Moreover, the geographic distribution of some virus-associated lymphomas points at a possible additional role of environmental or genetic factors.

The aim of this Special Issue is to update the knowledge on virus-associated lymphomas, focusing on the role of viruses in lymphoma etiopathogenesis, their influence on clinicopathological features and prognosis, and the use of viral components as targets for lymphoma treatment.

The Special Issue welcome papers on advances in the mechanisms through which viruses contribute to lymphoma development, especially those based on translational research. Moreover, studies on new therapeutic approaches for lymphoma based on virus targets will be greatly appreciated.

Dr. José-Tomás Navarro
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lymphoma
  • virus
  • etiopathogenesis
  • treatment
  • prognosis
  • Epstein–Barr
  • HIV
  • HHV-8
  • HTLV-I
  • HCV

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 2909 KiB  
Article
Relationship of Post-Transplant Lymphoproliferative Disorders (PTLD) Subtypes and Clinical Outcome in Pediatric Heart Transplant Recipients: A Retrospective Single Institutional Analysis/Experience of 558 Patients
by Yan Liu, Billy C. Wang, Craig W. Zuppan, Peter Chau, James Fitts, Richard Chinnock and Jun Wang
Cancers 2023, 15(3), 976; https://doi.org/10.3390/cancers15030976 - 03 Feb 2023
Cited by 5 | Viewed by 1600
Abstract
Post-transplant lymphoproliferative disorders (PTLD) are heterogenous lymphoproliferative disorders that develop as a consequence of immunosuppression in transplant recipients. We sought to determine if subtypes of PTLD correlated with different outcomes. We performed a retrospective review of PTLD occurring in pediatric heart transplant recipients. [...] Read more.
Post-transplant lymphoproliferative disorders (PTLD) are heterogenous lymphoproliferative disorders that develop as a consequence of immunosuppression in transplant recipients. We sought to determine if subtypes of PTLD correlated with different outcomes. We performed a retrospective review of PTLD occurring in pediatric heart transplant recipients. A total of 558 children and infants underwent cardiac transplantation at our institution between 1985 and 2019 and were followed until March 2021. Forty-nine of 558 patients developed PTLD (8.8%). As compared to older children (>one year of age), infant recipients (<three months of age) were less likely to develop PTLD. Monomorphic PTLDs (M-PTLD, 61%) was the most common subtype at initial diagnosis, followed by non-destructive (21%), polymorphic (14%), and classic Hodgkin lymphoma (cHL, 4%). Patients who underwent transplantation at a young age (<three months) had significantly lower rates of M-PTLD or cHL and a longer time from transplant to PTLD diagnosis as compared to children older than one year at transplant (p = 0.04). Although not reaching statistical significance, patients with a shorter time to PTLD diagnosis showed a trend toward higher rates of M-PTLD or cHL. As expected, the overall survival (OS) of patients with M-PTLD or cHL was significantly lower than patients with non-destructive or polymorphic PTLD. Full article
(This article belongs to the Special Issue Advances in Virus-Associated Lymphomas)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop